Anzeige
❌
Mehr »
Montag, 16.11.2026 - Börsentäglich über 12.000 News
Pelican AI: +34,75% in Frankfurt! Ist das erst der Anfang einer großen Kursrallye?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ME

WKN: A40CZ4 | ISIN: SE0022239950 | Ticker: 1YG0
Frankfurt
13.11.26 | 20:15
0,372 Euro
-12,06 % -0,051
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MENDUS AB Chart 1 Jahr
5-Tage-Chart
MENDUS AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,3560,43015.11.

Aktuelle News zur MENDUS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiMendus AB: Mendus announces initial immunological data from CADENCE and VITAL-CML indicating vididencel improves immune competence across indications145Vididencel-induced immune responses activate multiple compartments of the immune system based on initial samples from the ongoing CADENCE and VITAL-CML trialsThe data are consistent with earlier observations...
► Artikel lesen
MiMendus AB: Mendus AB Interim Report July - September 2026139Transforming immunotherapy for myeloid blood cancersGrowing evidence from completed and ongoing trials indicates that vididencel stimulates the immune system in a unique way, leading to broad tumor-directed...
► Artikel lesen
DiMendus AB: Mendus and NorthX Biologics expand collaboration to include production of memory NK cell therapies143Mendus and NorthX Biologics expand their collaboration to establish manufacturing of memory NK cells for therapeutic purposes, alongside the ongoing large-scale production of Mendus' lead product vididencel.The...
► Artikel lesen
05.10.Mendus AB: Mendus announces appointment of Hans Preusting as Chief Operating Officer175Hans Preusting (PhD, MBA) will join the management team as COO on 5 October 2026 and, as a consequence, step down from the Mendus board, where he has been an independent member since May 2021.This appointment...
► Artikel lesen
16.09.Mendus AB: Mendus announces initiation of the DIVA trial186Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies for myeloid blood cancers, today announced the initiation of the DIVA trial evaluating vididencel in combination...
► Artikel lesen
MENDUS Aktie jetzt für 0€ handeln
14.09.Mendus AB: Mendus draws under the second tranche of the Fenja Capital II A/S loan facility, extending cash runway into the second quarter of 2027204Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies for myeloid blood cancers, today announces that the Company will draw down SEK 16.5 million under a second...
► Artikel lesen
11.09.Mendus AB: Mendus reports positive read-out for first stage VITAL-CML trial271Mendus AB ("Mendus" publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies for myeloid blood cancers, today announced a positive read-out of the first safety and tolerability stage of...
► Artikel lesen
20.08.Earnings Call Transkript: Mendus senkt Kosten und treibt Krebsstudien im zweiten Quartal 2026 voran2
20.08.Mendus reduziert Verlust im zweiten Quartal dank Fortschritten bei Blutkrebsstudien1
20.08.Mendus AB: Mendus Ab Interim Report April- June 2026222Building momentum across myeloid blood cancers Clinical development gathered momentum during the second quarter of 2026, broadening the positioning of vididencel in acute myeloid leukemia (AML) and...
► Artikel lesen
08.07.Mendus AB: Mendus reports complete enrollment of the first stage of the VITAL-CML trial266VITAL-CML is a pivotal trial to confirm the safety and feasibility of vididencel immunotherapy in patients with suboptimal responses to current standard of care with tyrosine kinase inhibitors (TKIs)Completion...
► Artikel lesen
02.06.Mendus AB: Mendus reports long-term progression-free survival associated with broad immune activation in high-risk ovarian cancer210• ALISON trial data presented at ASCO demonstrate broad immune activation and support further evaluation of vididencel in combination approaches to improve durable disease control• Five participants...
► Artikel lesen
08.05.Mendus AB: Mendus AB Interim Report January - March 2026337Start of clinical program in chronic myeloid leukemia As part of its updated clinical strategy communicated end of 2025, Mendus is expanding clinical development of the lead product vididencel to include...
► Artikel lesen
21.04.Mendus AB: Mendus announces first patient enrolled in the VITAL-CML trial390Mendus AB ("Mendus" publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies for myeloid blood cancers, today announced that the first patient has been enrolled in the VITAL-CML trial...
► Artikel lesen
23.03.Mendus - Agreement to advance AML programme989Mendus has announced a new clinical collaboration with the Olivia Newton-John Cancer Research Institute (ONJCRI) to support the Phase Ib DIVA trial, evaluating lead cancer vaccine vididencel in chemo-unfit...
► Artikel lesen
13.02.Mendus - Vididencel set for a defining year772Mendus's FY25 results mark a strategically important year, culminating in the repositioning of lead asset vididencel in Q425. Clinical updates in acute myeloid leukaemia (AML) and ovarian cancer (OC)...
► Artikel lesen
11.02.Mendus AB: Mendus AB Year-end Report 2025313Capturing the immunotherapy opportunity in myeloid blood cancers In the fourth quarter of 2025, Mendus presented continued positive long-term survival data of the ADVANCE II trial in acute myeloid leukemia...
► Artikel lesen
16.12.25Mendus AB: Report from the Extraordinary General Meeting of Mendus AB (publ) on 16 December 2025412At the extraordinary general meeting (the "EGM") of Mendus AB (publ), reg. no. 556629-1786, (the "Company"), on 16 December 2025 adopted, inter alia, the following resolutions. For more detailed information...
► Artikel lesen
10.12.25Mendus - ASH 2025 update supports renewed strategy762Mendus has presented incremental clinical data for vididencel at the American Society of Hematology (ASH) 67th Annual Meeting, involving long-term follow-up for the ADVANCE II trial. This study is testing...
► Artikel lesen
01.12.25Mendus AB: Mendus Announces Large-Scale Vididencel GMP Production Milestone in Manufacturing Alliance with NorthX Biologics447Mendus AB (publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced the successful establishment of large-scale GMP production of its lead product...
► Artikel lesen
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1